MA34742B1 - Proteines de liaison à l'antigène - Google Patents

Proteines de liaison à l'antigène

Info

Publication number
MA34742B1
MA34742B1 MA36018A MA36018A MA34742B1 MA 34742 B1 MA34742 B1 MA 34742B1 MA 36018 A MA36018 A MA 36018A MA 36018 A MA36018 A MA 36018A MA 34742 B1 MA34742 B1 MA 34742B1
Authority
MA
Morocco
Prior art keywords
binding proteins
antigen binding
osm
methods
relates
Prior art date
Application number
MA36018A
Other languages
English (en)
Inventor
Gary Peter Bembridge
Chun-Wa Chung
Maria Feeney
Susannah Karen Ford
Ian Kirby
Ruth Mcadam
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45001764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34742(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA34742B1 publication Critical patent/MA34742B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Volume Flow (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention se réfère à des protéines de liaison à l'antigène et à des fragments de celles-ci qui se lient spécifiquement à l'oncostatine M (OSM), en particulier l'OSM humaine (hOSM), et qui inhibent la liaison de l'OSM au récepteur gp130 mais n'interagissent pas directement avec des résidus du site II. L'invention concerne aussi un procédé d'humanisation d'anticorps. Elle concerne en outre des compositions pharmaceutiques, des procédés de criblage et des méthodes de traitement médical.
MA36018A 2010-11-23 2013-06-19 Proteines de liaison à l'antigène MA34742B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41649510P 2010-11-23 2010-11-23
PCT/EP2011/070604 WO2012069433A2 (fr) 2010-11-23 2011-11-21 Protéines de liaison à l'antigène

Publications (1)

Publication Number Publication Date
MA34742B1 true MA34742B1 (fr) 2013-12-03

Family

ID=45001764

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36018A MA34742B1 (fr) 2010-11-23 2013-06-19 Proteines de liaison à l'antigène

Country Status (40)

Country Link
US (4) US8916695B2 (fr)
EP (3) EP2643352B1 (fr)
JP (2) JP6351973B2 (fr)
KR (2) KR101947356B1 (fr)
CN (1) CN103328508B (fr)
AR (1) AR083937A1 (fr)
AU (1) AU2011333878B2 (fr)
BR (1) BR112013012627A2 (fr)
CA (1) CA2818534A1 (fr)
CL (1) CL2013001466A1 (fr)
CO (1) CO6801627A2 (fr)
CY (1) CY1120448T1 (fr)
DK (1) DK2643352T3 (fr)
DO (1) DOP2013000113A (fr)
EA (1) EA027256B1 (fr)
ES (1) ES2681949T3 (fr)
HR (1) HRP20181092T1 (fr)
HU (1) HUE039412T2 (fr)
IL (1) IL226157B (fr)
JO (1) JO3455B1 (fr)
LT (1) LT2643352T (fr)
MA (1) MA34742B1 (fr)
ME (1) ME03069B (fr)
MX (1) MX351887B (fr)
MY (1) MY170404A (fr)
NZ (1) NZ610464A (fr)
PE (1) PE20140519A1 (fr)
PH (1) PH12013501036B1 (fr)
PL (1) PL2643352T3 (fr)
PT (1) PT2643352T (fr)
RS (1) RS57502B1 (fr)
SG (2) SG10201500388PA (fr)
SI (1) SI2643352T1 (fr)
SM (1) SMT201800397T1 (fr)
TR (1) TR201810773T4 (fr)
TW (1) TWI504609B (fr)
UA (1) UA111954C2 (fr)
UY (1) UY33743A (fr)
WO (1) WO2012069433A2 (fr)
ZA (1) ZA201303541B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013500703A1 (en) 2010-10-13 2013-05-20 Janssen Biotech Inc Human oncostatin m antibodies and methods of use
MX351887B (es) 2010-11-23 2017-11-01 Glaxo Group Ltd Proteinas de union a antigeno para oncostatina m (osm).
US9550828B2 (en) 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
EP3197480A1 (fr) 2014-09-24 2017-08-02 Universita' Degli Studi Di Padova Composition pour induire la mobilisation des cellules souches de la moelle osseuse
EP3250599B1 (fr) * 2015-01-29 2021-04-14 Oxford University Innovation Limited Biomarqueur
GB201614627D0 (en) * 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
FR3090637A1 (fr) * 2018-12-21 2020-06-26 Universite De Poitiers Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations.
US11633457B2 (en) 2019-04-11 2023-04-25 Boise State University Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use
TW202607038A (zh) 2020-10-19 2026-02-16 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE69127749T2 (de) 1990-03-20 1998-04-16 The Trustees Of Columbia University In The City Of New York, New York, N.Y. Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5783672A (en) * 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
WO1997043316A1 (fr) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Molecules physiologiquement actives a demi-vies prolongees et methode d'utilisation de ces dernieres
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US5958442A (en) * 1997-10-24 1999-09-28 Bristol-Myers Squibb Company Oncostatin M for treating inflammation
BR9908226A (pt) 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (fr) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
CA2388245C (fr) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. L'utilisation de cellules de rat adaptess exemptes de serum pour produire de polypeptides heterologues
DE60037648T2 (de) * 2000-04-21 2010-06-17 Conaris Research Institute Ag Fusionsproteine, die zwei lösliche gp130 Moleküle enthalten
EP1332209B1 (fr) 2000-09-08 2009-11-11 Universität Zürich Groupes de proteines a domaines de repetition comprenant des modules de repetition
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1355919B1 (fr) 2000-12-12 2010-11-24 MedImmune, LLC Molecules a demi-vies longues, compositions et utilisations de celles-ci
AU2002368077B2 (en) * 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1423510A4 (fr) 2001-08-03 2005-06-01 Glycart Biotechnology Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
AU2002319544B2 (en) 2001-08-10 2008-07-10 Aberdeen University Antigen binding domains from fish
CA2531238C (fr) 2003-07-04 2015-02-24 Affibody Ab Polypeptides presentant une affinite de liaison pour le recepteur 2 du facteur de croissance epidermique humain (her2)
WO2005019255A1 (fr) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteines de la lipocaline lacrymale
PE20090047A1 (es) * 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
GB0407197D0 (en) * 2004-03-30 2004-05-05 Glaxo Group Ltd Immunoglobulins
BRPI0509367A (pt) * 2004-03-30 2007-09-11 Glaxo Group Ltd anticorpo, fragmento de ligação de antìgeno, composição farmacêutica, métodos de tratar um paciente humano afligido com uma doença ou distúrbio, de triar um anticorpo, e de detectar hosm em uma amostra biológica, uso de um anticorpo terapêutico ou fragmento de ligação de antìgeno, medicamento, vetor, polunucleotìdeo, célula hospedeira recombinante estavelmente transformada ou transfectada, e, processo para a fabricação de um anticorpo terapêutico
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
KR101318611B1 (ko) 2005-07-22 2013-11-13 교와 핫꼬 기린 가부시키가이샤 유전자 재조합 항체 조성물
MX2008014842A (es) * 2006-05-25 2009-02-17 Glaxo Group Ltd Anticuerpos humanizados contra interleuquina-18 modificados.
EP1958957A1 (fr) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprenant un partie caractéristique des protéines appellées "Knottins"
WO2010056893A1 (fr) * 2008-11-13 2010-05-20 Imclone Llc Humanisation et optimisation d’affinité d’anticorps
PH12013500703A1 (en) * 2010-10-13 2013-05-20 Janssen Biotech Inc Human oncostatin m antibodies and methods of use
MX351887B (es) 2010-11-23 2017-11-01 Glaxo Group Ltd Proteinas de union a antigeno para oncostatina m (osm).

Also Published As

Publication number Publication date
KR20130119948A (ko) 2013-11-01
EA201390537A1 (ru) 2014-01-30
LT2643352T (lt) 2018-08-10
WO2012069433A3 (fr) 2012-08-09
SMT201800397T1 (it) 2018-09-13
TWI504609B (zh) 2015-10-21
JP6351973B2 (ja) 2018-07-04
ES2681949T3 (es) 2018-09-17
JP2014507373A (ja) 2014-03-27
US20150064201A1 (en) 2015-03-05
DOP2013000113A (es) 2013-12-15
HUE039412T2 (hu) 2018-12-28
CO6801627A2 (es) 2013-11-29
PL2643352T3 (pl) 2018-10-31
ZA201303541B (en) 2014-11-26
MX2013005843A (es) 2013-07-05
AR083937A1 (es) 2013-04-10
US20130251724A1 (en) 2013-09-26
SI2643352T1 (sl) 2018-12-31
IL226157A0 (en) 2013-06-27
PH12013501036A1 (en) 2013-07-15
SG10201500388PA (en) 2015-03-30
PT2643352T (pt) 2018-08-01
CY1120448T1 (el) 2019-07-10
DK2643352T3 (en) 2018-07-30
PE20140519A1 (es) 2014-04-30
JO3455B1 (ar) 2020-07-05
HRP20181092T1 (hr) 2018-09-21
RS57502B1 (sr) 2018-10-31
MX351887B (es) 2017-11-01
KR101947356B1 (ko) 2019-02-12
US8916695B2 (en) 2014-12-23
TR201810773T4 (tr) 2018-08-27
CN103328508A (zh) 2013-09-25
EP2643352A2 (fr) 2013-10-02
BR112013012627A2 (pt) 2016-10-04
WO2012069433A2 (fr) 2012-05-31
EP3369744A1 (fr) 2018-09-05
IL226157B (en) 2020-10-29
US20170152312A1 (en) 2017-06-01
MY170404A (en) 2019-07-27
SG190232A1 (en) 2013-06-28
ME03069B (fr) 2019-01-20
AU2011333878A1 (en) 2013-05-09
CL2013001466A1 (es) 2014-06-27
UA111954C2 (uk) 2016-07-11
EP3211009A1 (fr) 2017-08-30
US10808029B2 (en) 2020-10-20
UY33743A (es) 2012-06-29
EP2643352B1 (fr) 2018-05-02
CA2818534A1 (fr) 2012-05-31
AU2011333878B2 (en) 2016-01-14
US20210017270A1 (en) 2021-01-21
PH12013501036B1 (en) 2019-05-10
EA027256B1 (ru) 2017-07-31
CN103328508B (zh) 2015-12-16
KR20180110199A (ko) 2018-10-08
JP2017078072A (ja) 2017-04-27
NZ610464A (en) 2015-02-27
TW201235358A (en) 2012-09-01
US9605063B2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
MA35208B1 (fr) Protéines de liaison à bcma (cd269/tnfrsf17)
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
MA33387B1 (fr) Polypeptides et procede de traitement
CY1120448T1 (el) Αντιγονοδεσμευτικες πρωτεϊνες σε ογκοστατινη μ (osm)
SG151292A1 (en) Immunoglobulins
UA130540C2 (uk) Композиція антитіла b7-h4
WO2008105886A3 (fr) Anticorps spécifiques fcgriib humanisés, et leurs procédés d'utilisation
MA38161A1 (fr) Anticorps anti-bmp-6
MA32725B1 (fr) Anticorps contre l'il 17 humaine et utilisations associees
PE20091196A1 (es) Anticuerpos contra el vegf completamente humano, composiciones y metodos
MY159787A (en) High affinity antibodies to human il-6 receptor
NO20054170L (no) Antistoff mot human IL-21 reseptor og anvendelser derav
WO2005110474A3 (fr) ANTICORPS SPÉCIFIQUES FcϜRIIB HUMANISÉS ET MÉTHODES D’UTILISATION
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MX2009006891A (es) Anticuerpos cd44.
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
WO2006102395A3 (fr) Systemes et methodes d'administration pour le diagnostic et le traitement de maladies cardio-vasculaires
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
RU2011142183A (ru) Средство для лечения ревматоидного артрита
EP2680004A3 (fr) Compositions et procédés pour la détection du cancer
MY185086A (en) Human anti-b7rp1 neutralizing antibodies